Detalles de la búsqueda
1.
Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis.
N Engl J Med
; 376(7): 652-662, 2017 02 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-28199814
2.
Clinical outcomes in patients switched from adalimumab to baricitinib due to non-response and/or study design: phase III data in patients with rheumatoid arthritis.
Ann Rheum Dis
; 78(7): 890-898, 2019 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-31040122
3.
Relationship between disease activity and patient-reported outcomes in rheumatoid arthritis: Post hoc analyses of overall and Japanese results from two phase 3 clinical trials.
Mod Rheumatol
; 28(6): 950-959, 2018 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-29278006
4.
Determinants of Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity in patients with rheumatoid arthritis: A post hoc analysis of overall and Japanese results from phase 3 clinical trials.
Mod Rheumatol
; 28(6): 960-967, 2018 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-29278339
5.
Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study.
Ann Rheum Dis
; 76(11): 1853-1861, 2017 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-28798049
6.
Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study.
Ann Rheum Dis
; 76(1): 88-95, 2017 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-27689735
7.
Patient-reported outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON).
Ann Rheum Dis
; 76(4): 694-700, 2017 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-27799159
8.
Psychometric properties of morning joint stiffness duration and severity measures in patients with moderately to severely active rheumatoid arthritis.
Health Qual Life Outcomes
; 15(1): 239, 2017 Dec 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-29212515
9.
Psychometric properties of the single-item measure, severity of worst tiredness, in patients with moderately to severely active rheumatoid arthritis.
Health Qual Life Outcomes
; 15(1): 237, 2017 Dec 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-29208004
10.
Defining Pain That Does Not Interfere With Activities Among Rheumatoid Arthritis Patients.
Arthritis Care Res (Hoboken)
; 73(5): 626-632, 2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-32058654
11.
Health Care Effect of Disease-Modifying Antirheumatic Drug Use on Patients with Rheumatoid Arthritis.
J Manag Care Spec Pharm
; 25(8): 879-887, 2019 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-31347977
12.
Patient Perceptions of Unmet Medical Need in Rheumatoid Arthritis: A Cross-Sectional Survey in the USA.
Rheumatol Ther
; 6(3): 461-471, 2019 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-31385264
13.
Use of daily electronic patient-reported outcome (PRO) diaries in randomized controlled trials for rheumatoid arthritis: rationale and implementation.
Trials
; 20(1): 182, 2019 Mar 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-30902094
14.
Effect of Baricitinib and Adalimumab in Reducing Pain and Improving Function in Patients with Rheumatoid Arthritis in Low Disease Activity: Exploratory Analyses from RA-BEAM.
J Clin Med
; 8(9)2019 Sep 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-31492040
15.
Correction to: Use of daily electronic patient-reported outcome (PRO) diaries in randomized controlled trials for rheumatoid arthritis: rationale and implementation.
Trials
; 20(1): 322, 2019 06 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-31164168
16.
Relative Impact of Pain and Fatigue on Work Productivity in Patients with Rheumatoid Arthritis from the RA-BEAM Baricitinib Trial.
Rheumatol Ther
; 6(3): 409-419, 2019 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-31228100
17.
Achieving Pain Control in Rheumatoid Arthritis with Baricitinib or Adalimumab Plus Methotrexate: Results from the RA-BEAM Trial.
J Clin Med
; 8(6)2019 Jun 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-31212775
18.
Examination of Patient-Reported Outcomes in Association with TNF-Inhibitor Treatment Response: Results from a US Observational Cohort Study.
Rheumatol Ther
; 5(1): 215-229, 2018 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-29322372
19.
Estimating the response and economic burden of rheumatoid arthritis patients treated with biologic disease-modifying antirheumatic drugs in Taiwan using the National Health Insurance Research Database (NHIRD).
PLoS One
; 13(4): e0193489, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-29624580
20.
Comparative effects of raloxifene and alendronate on fracture outcomes in postmenopausal women with low bone mass.
Bone
; 40(4): 843-51, 2007 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-17182297